What is the difference between Platinib and Seputinib?

Pralsetinib and seputinib are both targeted therapeutic drugs targeting RET gene mutations, but they are significantly different in many aspects.

First of all, from the perspective of the drug's mechanism of action, Platinib is an irreversible targeted drug that mainly exerts a therapeutic effect by inhibiting the kinase activity of RET, ROS1 and ALK, and is highly selective for RET; while Seputinib is a reversible targeted drug that achieves therapeutic effects by inhibiting the kinase activity of RET. It also inhibits VEGFR and BRAF V600E kinase, so its target specificity is relatively low.

Secondly, the two also differ in terms of security. Although both drugs can cause some side effects, the specific manifestations and severity vary. For example, platinib may cause side effects such as nausea, diarrhea, and high blood pressure, while seputinib may cause side effects such as high blood pressure, nausea, and fatigue. Therefore, when choosing a medication, doctors will consider the patient's specific situation and tolerance.

In addition, there are differences in indications between the two. Platinib is mainly used to treat RET fusion-positive non-small cell lung cancer, medullary thyroid cancer, etc.; while seputinib has a wider scope of application. In addition to treating cancers with RET mutations, it can also be used to treat other types of cancer such as non-small cell lung cancer with ROS1 and ALK mutations.

Finally, there are also differences in usage and dosage between the two. The usually recommended dose of platinib is 400 mg once a day; while the dose of seputinib is determined based on the patient's weight, and lower doses are recommended for patients less than 50 kg.

In general, there are obvious differences between platinib and seputinib in terms of mechanism of action, safety, indications, usage and dosage. Therefore, when choosing which drug to use, the decision needs to be made based on the patient's specific situation and the doctor's advice.